Drugs Made In America Acquisition II Corp.
DMIIU- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002040475
No open-market purchases or sales by Drugs Made In America Acquisition II Corp. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $35.0M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Drugs Made In America Acquisition II Corp. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 75 | 1 | 30 | −44 |
| Shares | 45.8M | 100.0K | 11.6M | −34.1M (−74.7%) |
| Value | $455.8M | $994.5K | $116.0M | −$338.8M (−74.5%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Drugs Made In America Acquisition II Corp. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| L1 Global Manager Pty Ltd | 100,000 | $1.00M | 0.66% |
| UBS Group AG | 93,470 | $936.1K | 0.00% |
| Prelude Capital Management, LLC | 50,000 | $500.8K | 0.04% |
| Stoic Point Capital Management LLC | 50,000 | $500.8K | 0.42% |
| Rangeley Capital, LLC | 32,551 | $326.0K | 0.28% |
| Susquehanna International Group, LLP | 25,112 | $251.1K | 0.00% |
| Boothbay Fund Management, LLC | 25,000 | $250.4K | 0.01% |
| Robinson Capital Management, LLC | 25,000 | $250.0K | 0.10% |
Sold out (52)
Institutions that held Drugs Made In America Acquisition II Corp. at the end of Q3 2025 and filed for Q4 2025 without it.
Not filed for Q4 2025 yet (1)
Institutions that held Drugs Made In America Acquisition II Corp. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Maso Capital Partners Ltd | 100,000 | $994.5K |